Biofourmis, a provider of digital therapeutics based in Boston, agreed to acquire Biovotion, a developer of a clinical-grade wearable biosensor platform. Financial terms were not disclosed. "Biovotion had been a trusted partner for many years as we have leveraged each other's technologies across numerous clinical, commercial and research applications. We are thrilled to add Everion to the Biovitals ecosystem, which will continue to help our clients achieve their goals such as demonstrating the value of pharmacotherapy, managing chronic diseases, predicting and preventing adverse events, and improving clinical outcomes—and ultimately reducing healthcare costs," Kuldeep Singh Rajput, Biofourmis CEO and founder.